Streetbeat News

Stock Prices

DLTR

JP Morgan analyst Matthew Boss has maintained a Neutral rating on Dollar Tree (NASDAQ:DLTR) and reduced the price target from $125 to $122.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 7:22 pm

VIBEF

Vibe Growth Corp (OTCQB:VIBEF) reported mixed Q3 2023 results with a revenue decline of 8.1% to $3.39 million and a net loss of $1.34 million, consistent with the same period in 2022. However, the company saw an improvement in dispensary gross margin to 49.7% and a positive EBITDA of $1.17 million for the quarter. CEO Mark Waldron attributed growth to strategic changes and cost reductions. VIBEF's stock was trading at $0.021 per share.

Portfolio Pulse from Patricio Liddle

November 30, 2023 | 7:22 pm

SNOW

Truist Securities analyst Joel Fishbein has maintained a Buy rating on Snowflake (NYSE:SNOW) and increased the price target from $200 to $210.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 7:21 pm

QS

Truist Securities analyst Jordan Levy has maintained a Hold rating on QuantumScape (NYSE:QS) and increased the price target from $6 to $7.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 7:18 pm

VRT

JP Morgan analyst Stephen Trent has maintained an Overweight rating on Vertiv Holdings (VRT) and increased the price target from $45 to $48.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 7:16 pm

OKTA

Truist Securities analyst Joel Fishbein has maintained a Hold rating on Okta (NASDAQ:OKTA) but reduced the price target from $75 to $70.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 7:16 pm

GSK

PFE

GSK plc's CEO Emma Walmsley is optimistic about the growth potential of their RSV vaccine, Arexvy, expecting sales to exceed £1 billion in its first year. The vaccine has had a strong start in the U.S. and has been approved in Europe, Japan, and other regions. Despite competition from Pfizer Inc and concerns over litigation costs related to Zantac, Walmsley believes these will not affect GSK's capital allocation strategy. GSK shares saw a 1.03% increase to $35.86.

Portfolio Pulse from Vandana Singh

November 30, 2023 | 7:15 pm

FUV

Arcimoto Inc (NASDAQ:FUV) stock is trading lower after a recent rally, with no company-specific news to justify the surge. The selloff may be due to a late filing notice from Nasdaq for its quarterly report and negative reports highlighting financial concerns, such as dwindling cash reserves. Retail traders' concerns about the market resurgence ending and profit-taking after the stock's significant appreciation could also be contributing factors. FUV shares are down 68% year-to-date but up 60% over the past week.

Portfolio Pulse from Adam Eckert

November 30, 2023 | 7:15 pm

CRM

JP Morgan analyst Mark Murphy has maintained an Overweight rating on Salesforce (NYSE:CRM) and increased the price target from $240 to $260.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 7:14 pm

CBRL

IMGN

LIZI

POET

PSTG

REX

SNGX

The Nasdaq fell over 100 points while the Dow Jones gained around 300 points. Cracker Barrel's shares slid after reporting a decrease in Q1 revenues and adjusted EPS, missing consensus estimates. Soligenix, REX American Resources, and ImmunoGen saw significant share price increases, with ImmunoGen being acquired by AbbVie. Lizhi Inc., POET Technologies, and Pure Storage experienced notable declines in share prices following their respective earnings reports and public offering news. The health care sector rose, while communication services fell. Oil and gold prices dropped, while silver and copper rose. European shares closed mostly higher, and Asian markets ended on a positive note. U.S. economic data showed mixed results with a slight increase in personal spending and income, a rise in jobless claims, and a drop in pending home sales.

Portfolio Pulse from Lisa Levin

November 30, 2023 | 7:12 pm